What side effects may ixazomib cause?

Ixazomib, in combination with lenalidomide and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least one prior line of therapy.

What side effects may ixazomib cause?

In addition to its intended therapeutic effects, a medication may cause certain adverse reactions. While not all side effects may occur, if they do, medical attention may be required.

Consult your doctor immediately if you experience any of the following side effects:

During clinical monitoring, patients may present with a variety of symptoms, among which the more common ones include black, tarry stools; swelling or edema of the face, arms, hands, lower legs, or feet; as well as a burning, numb, tingling, or painful sensation. In addition, chills, cough, dark-colored urine, diarrhea, dizziness, fever, and headache are also relatively common, which may be accompanied by itching or skin rash, light-colored stools, loss of appetite, pain in the lower back or side, nausea, numbness, tingling, or pain in the hands or feet, and painful or difficult urination.

Other common manifestations include pale skin, rapid weight gain, flat or slightly raised skin rashes, redness or discoloration of the skin, sore throat, stomach pain, tingling sensation in the hands or feet, ulcers, sores, or white spots in the mouth, foul breath, unsteadiness or clumsiness of movement, unusual bleeding or bruising, unusual tiredness or weakness, abnormal weight gain or loss, vomiting of blood, weakness in the arms, hands, legs, or feet, and yellowing of the eyes or skin. In less common cases, symptoms may involve bleeding gums, blood in the urine or stools, or pinpoint red spots on the skin.

Rare symptoms include blistering, peeling, or loosening of the skin, nosebleeds, increased menstrual flow, joint or muscle pain, red skin lesions (often with a purple center), and redness or inflammation of the eyes. These manifestations require comprehensive evaluation in combination with the specific clinical context.

Precautions for Use During Pregnancy and Lactation

Pregnancy

Use in pregnant women may cause fetal harm.

Human data on the potential effects of ixazomib on pregnancy or embryonic/fetal development are currently unavailable.

Animal Studies

In rats and rabbits, ixazomib induced embryo-fetal toxicity when administered at doses resulting in exposures slightly higher than those observed in patients receiving the recommended dose.

Fetal skeletal variations/anomalies (caudal vertebral fusion, increased number of lumbar vertebrae, complete supernumerary ribs) were observed in rabbit studies.

In rat studies, decreased fetal body weight, a trend toward reduced fetal survival rate, and increased post-implantation loss were observed.

Enhancing the Effectiveness of Healthcare Team Collaboration

Ixazomib is currently the only oral proteasome inhibitor indicated for the treatment of multiple myeloma. Therefore, all healthcare professionals, including physicians, specialists, advanced practice providers, nurses, and pharmacists, should be familiar with the drug’s indications, dosage, adverse reaction profile, potential drug interactions, and necessary monitoring requirements. With the increasing use of ixazomib and its diverse adverse reactions, an interprofessional team, regardless of specialty, must conduct close monitoring of patients.

Clinicians should monitor patients’ liver function, platelet counts, and neutrophil counts. The healthcare team should coordinate actions and share information; if patients develop skin rashes, malaise, diarrhea, or other potential adverse reactions during ixazomib treatment, timely dose adjustment or treatment regimen modification should be implemented. This interprofessional collaboration model will help improve the likelihood of successful outcomes in patients receiving the triple therapy regimen containing dexamethasone and lenalidomide, thereby optimizing the therapeutic effect of multiple myeloma treatment.